Financial Implications of Short Stay Pediatric Hospitalizations.


Journal

Pediatrics
ISSN: 1098-4275
Titre abrégé: Pediatrics
Pays: United States
ID NLM: 0376422

Informations de publication

Date de publication:
01 04 2022
Historique:
accepted: 08 12 2021
pubmed: 1 4 2022
medline: 14 5 2022
entrez: 31 3 2022
Statut: ppublish

Résumé

Observation status (OBS) stays incur similar costs to low-acuity, short-stay inpatient (IP) hospitalizations. Despite this, payment for OBS is likely less and may represent a financial liability for children's hospitals. Thus, we described the financial outcomes associated with OBS stays compared to similar IP stays by hospital and payer. We conducted a retrospective cohort study of clinically similar pediatric OBS and IP encounters at 15 hospitals contributing to the revenue management program in 2017. Clinical and demographic characteristics were described. For each hospitalization, the cost coverage ratio (CCR) was calculated by dividing revenue by estimated cost of hospitalization. Differences in CCR were evaluated using Wilcoxon rank sum tests and results were stratified by billing designation and payer. CCR for OBS and IP stays were compared by institution, and the estimated increase in revenue by billing OBS stays as IP was calculated. OBS was assigned to 70 981 (56.9%) of 124 789 hospitalizations. Use of OBS varied across hospitals (8%-86%). For included hospitalizations, OBS stays were more likely than IP stays to result in financial loss (57.0% vs 35.7%). OBS stays paid by public payer had the lowest median CCR (0.6; interquartile range [IQR], 0.2-0.9). Paying OBS stays at the median IP rates would have increased revenue by $167 million across the 15 hospitals. OBS stays were significantly more likely to result in poor financial outcomes than similar IP stays. Costs of hospitalization and billing designations are poorly aligned and represent an opportunity for children's hospitals and payers to restructure payment models.

Sections du résumé

BACKGROUND
Observation status (OBS) stays incur similar costs to low-acuity, short-stay inpatient (IP) hospitalizations. Despite this, payment for OBS is likely less and may represent a financial liability for children's hospitals. Thus, we described the financial outcomes associated with OBS stays compared to similar IP stays by hospital and payer.
METHODS
We conducted a retrospective cohort study of clinically similar pediatric OBS and IP encounters at 15 hospitals contributing to the revenue management program in 2017. Clinical and demographic characteristics were described. For each hospitalization, the cost coverage ratio (CCR) was calculated by dividing revenue by estimated cost of hospitalization. Differences in CCR were evaluated using Wilcoxon rank sum tests and results were stratified by billing designation and payer. CCR for OBS and IP stays were compared by institution, and the estimated increase in revenue by billing OBS stays as IP was calculated.
RESULTS
OBS was assigned to 70 981 (56.9%) of 124 789 hospitalizations. Use of OBS varied across hospitals (8%-86%). For included hospitalizations, OBS stays were more likely than IP stays to result in financial loss (57.0% vs 35.7%). OBS stays paid by public payer had the lowest median CCR (0.6; interquartile range [IQR], 0.2-0.9). Paying OBS stays at the median IP rates would have increased revenue by $167 million across the 15 hospitals.
CONCLUSIONS
OBS stays were significantly more likely to result in poor financial outcomes than similar IP stays. Costs of hospitalization and billing designations are poorly aligned and represent an opportunity for children's hospitals and payers to restructure payment models.

Identifiants

pubmed: 35355068
pii: 185686
doi: 10.1542/peds.2021-052907
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2022 by the American Academy of Pediatrics.

Déclaration de conflit d'intérêts

CONFLICT OF INTEREST DISCLOSURES: The authors have indicated they have no conflicts of interest relevant to this article to disclose.

Auteurs

David C Synhorst (DC)

Children's Mercy Kansas City, Kansas City, Missouri.

Matt Hall (M)

Children's Mercy Kansas City, Kansas City, Missouri.
Children's Hospital Association, Lenexa, Kansas.

Michelle L Macy (ML)

Department of Pediatrics and.
Northwestern University Feinberg School of Medicine and.

Jessica L Bettenhausen (JL)

Children's Mercy Kansas City, Kansas City, Missouri.
University of Kansas School of Medicine, Kansas City, Kansas.

Jessica L Markham (JL)

Children's Mercy Kansas City, Kansas City, Missouri.
University of Kansas School of Medicine, Kansas City, Kansas.

Samir S Shah (SS)

Division of Hospital Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
University of Cincinnati College of Medicine, Cincinnati, Ohio.

Anthony Moretti (A)

Department of Quality and Utilization Management, Loma Linda Children's Hospital, Loma Linda, California.
Blue Shield of California, Oakland, California.

Mehul V Raval (MV)

Division of Pediatric Surgery, Department of Surgery, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Surgical Outcomes Quality Improvement Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Yao Tian (Y)

Surgical Outcomes Quality Improvement Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Heidi Russell (H)

Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio.

Jonathan Hartley (J)

Children's Mercy Kansas City, Kansas City, Missouri.

Rustin Morse (R)

Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.

James C Gay (JC)

Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH